z-logo
open-access-imgOpen Access
Insights into the Roles of Midazolam in Cancer Therapy
Author(s) -
Jinghua Jiao,
Yuheng Wang,
Sun Xiao,
Xiaojing Jiang
Publication year - 2017
Publication title -
evidence-based complementary and alternative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.552
H-Index - 90
eISSN - 1741-4288
pISSN - 1741-427X
DOI - 10.1155/2017/3826506
Subject(s) - midazolam , medicine , cancer , sedation , pharmacology , mechanism (biology) , drug , adjuvant , anesthetic , benzodiazepine , blockade , sedative , bioinformatics , oncology , anesthesia , receptor , biology , philosophy , epistemology
With its high worldwide mortality and morbidity, cancer has gained increasing attention and novel anticancer drugs have become the focus for cancer research. Recently, studies have shown that most anesthetic agents can influence the activity of tumor cells. Midazolam is a γ -aminobutyric acid A (GABA A ) receptor agonist, used widely for preoperative sedation and as an adjuvant during neuraxial blockade. Some studies have indicated the potential for midazolam as a novel therapeutic cancer drug; however, the mechanism by which midazolam affects cancer cells needs to be clarified. This systematic review aims to summarize the progress in assessing the molecular mechanism of midazolam as an anticancer agent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom